23
Views
3
CrossRef citations to date
0
Altmetric
Review

AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction

&
Pages 891-902 | Published online: 10 Jan 2014

References

  • American Heart Association. Heart Disease and Stroke Statistics — 2004 Update. American Heart Association, TX, USA (2004).
  • Timmermans PB, Chiu AT, Herblin WF et al. Angiotensin II-receptor subtypes. Am. Hypertens. 5,406–410 (1992).
  • Unger T, Chung 0, Csikos T et al. Angiotensin receptors. J. Hypertens. 14\(Suppl. 5), S95—S103 (1996).
  • Harada K, Sugaya T, Murakami K et al. Angiotensin II Type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 100 (20), 2093–2099 (1999).
  • Dzau VJ, Sasamura H, Hem L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J. Hypertens. 11\(Suppl. 3), S13—S18 (1993).
  • •Nice review paper on angiotensin II receptor subtypes and blockers.
  • Burnier M. Angiotensin II Type 1 receptor blockers Circulation 103,904–912 (2001).
  • Janiak P, Pillon A, Prost JF et al Role of angiotensin subtype 2-receptor in neointima formation after vascular surgery. Hypertension 20,737–745 (1992).
  • Stoll M, Steckelings M, Paul M et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin. Invest. 95, 651–657 (1995).
  • Nakajima M, Hutchinson HG, Fujinaga M et al. The angiotensin II Type 2 (AT2) antagonizes the growth effect of the AT1 receptor. Proc. Natl Acad. Sci. USA 92, 10663–10667 (1995).
  • Velazquez EJ, Pfeffer MA. Acute heart failure complicating acute coronary syndromes. Circulation 109,440–442 (2004).
  • Pfeffer MA, Pfeffer JM, Lamas GA. Development and prevention of congestive heart failure following myocardial infarction. Circulation 87(5 Suppl.), IV120-1V125 (1993).
  • Mitchell GF, Lamas GA, Pfeffer MA. Ventricular remodeling after myocardial infarction. Adv. EAR Med. Biol. 346, 265–276 (1993).
  • •• Important paper on left ventricular dilation and prognosis in postmyocardial infarction (J\/II) patients.
  • White HD, Norris MN, Brown MA et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76(1), 44–51 (1987).
  • Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am. J. PhysioL 260, H1406—H1414 (1991).
  • Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol induced myocardial necrosis in rats. Circ. Res. 75(1), 105–113 (1994).
  • Fletcher PJ, Pfeffer JM, Pfeffer MA, Braunwald E. Left ventricular diastolic pressure—volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ. Res. 49(3), 618–626 (1981).
  • Pfeffer MA, Pfeffer JM, Fishbein MC et al. Myocardial infarct size and ventricular function in rats. Circ. Res. 44(4), 503–512 (1979).
  • •• Important pioneer study on the effect of captopril in a post-MI animal model.
  • Pfeffer JM, Pfeffer MA, Braunwald E. Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation, 75,1149–1155 (1987).
  • Lamas GA, Pfeffer MA. Increased left ventricular volume following myocardial infarction in man. Am. Heart J. 111(1), 30–35 (1986).
  • Pfeffer MA, Lamas GA, Vaughan DE et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl. J. Med. 319(2), 80–86 (1988).
  • Lamas GA, Pfeffer MA. Left ventricular remodeling after acute myocardial infarction: clinical course and beneficial effects of angiotensin-converting enzyme inhibition. Am. Heart J. 121,1194–1202 (1991).
  • Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. The SAVE investigators. N Engl. J. Med. 327,669–677 (1992).
  • Sutton MS, Pfeffer MA, Plappert T et al. Quantitative two-dimentional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. Circulation 89,68–75 (1993).
  • The acute infarction ramipril efficacy (AIRE) study investigators: effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet342, 821–828 (1993).
  • Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. TRAndolapril Cardiac Evaluation (TRACE) Study Group. N Engl. J Med. 333 (25), 1670–1676 (1995).
  • ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet, 345, 669–685 (1995).
  • Gruppo Italian° per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet, 343,1115–1122 (1994).
  • Zisman LS, Abraham WT, Meixell GE et al. Angiotensin II formation in the intact human heart: predominance of angiotensin-converting enzyme pathway. Clin. Invest. 96,1490–1496 (1995).
  • Kokkonen JO, Saarinen J, Kovanen PT. Angiotensin II formation in human heart: an ACE or non-ACE-mediated pathway? Ann. Med. (Suppl. 1), 9–13 (1998).
  • •Great review for different angiotensin-converting enzyme (ACE) pathways in human heart.
  • Urata H, Nishimura H, Ganten D. Mechanism of angiotensin II formation in humans. Euz: Heart J. 16(Suppl. N), 79–85 (1995).
  • Wei CC, Meng QC, Palmer R et al. Evidence for angiotensin-converting enzyme and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. Circulation 99,2583–2589 (1999).
  • van den Meiracker AH, Man in't Veld AJ, Admiraal PJ et al. Partial escape of angiotensin-converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J. Hypertens. 8,803–812 (1992).
  • •Important article explaining renin—angiotensin—aldosterone system escape.
  • Pitt B. Escape of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc. Drugs Ther 9,145–149 (1995).
  • Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. CUIT: Hypertens. Rep. 5(5) 408–417 (2003).
  • MacFadyen RJ, Lee AFC, Pringle SD et al. How often are angiotensin II and aldosterone concentration raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82,57–61 (1999).
  • Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure Patients on chronic ACE inhibitor therapy: a longitudinal study. Eur I Heart Fail. 1(4), 401–406 (1999).
  • Jorde UP, Vittoro T, Katz SD et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 106,1055–1057 (2002).
  • Ciocoira M, Zanolla L, Franceschini L et al. Relationship of aldosterone escape despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. I CardioL 89(4), 403–407 (2002).
  • Roig E, Perez-Villa F, Morales M et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 21,53–57 (2000).
  • Califf RM, Cohn JN. Cardiac protection: evolving role of angiotensin receptor blockers. Am. Heart J. 139, S15—S22 (2000).
  • Peterson RC, Dunlap ME. Angiotensin II receptor blockers in the treatment of heart failure. Congest. Heart Fail. 8(5), 246–250 (2002).
  • Schieffer B, Wirger A, Meybrunn et al., Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II Type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89(5), 2273–2283 (1994).
  • ••Classic animal study of an angiotensinreceptor blocker (ARB) post MI.
  • Jam M, Liao R, Ngoy S et al., Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodeling in rats. Cardiovascular Res. 46,66–72 (2000).
  • •Nice review of different ARBs and their pharmacologic properties.
  • Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can. J. CardioL 15\(Suppl. 9, F26—F28 (1999).
  • Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 51(5), 820–845 (1996).
  • Thurmann PA. Valsartan: a novel angiotensin Type 1 receptor antagonist. Expert Opin. Pharmacother.1 (2), 337–350 (2000).
  • Adams MA, Trudeau L. Irbesartan: review of pharmacology and comparative properties. Can. J. Clin. PharmacoL 7(1), 22–31 (2000).
  • Stoukides CA, McVay HJ, Kaul AF. Candesartan cilexetil: an angiotensin II receptor blacker. Ann. Pharmacother. 33(12) 1287–1298 (1999).
  • Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Prem. 10 (Suppl. 1), 6–11 (2001).
  • Hedner T. The clinical profile of the angiotensin II blacker eprosartan. Hypertens. 20 (Suppl. 5), 533—S38 (2003).
  • Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxamil, an angiotensin II type AT1 receptor antagonist. I Hypertens. 19\(Suppl. 1), S3—S14 (2001).
  • Weber MA. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold? J. Renin Angiotensin Aldosterone Syst. 4(2), 62–73 (2003).
  • McInnes GT, O'Kane KP, Istad H et al. Comparison of the AT1-receptor blacker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. I Hum. Hypertens. 14(4), 263–269 (2000).
  • Pitt B, Segal R, Martinez FA et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly study [ELITE]). Lancet 349, 747–752 (1997).
  • Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial — the losartan heart failure survival study ELITE II. Lancet 355,1582–1587 (2000).
  • Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. OPtimal Therapy In Myocardial infarction with the Angiotensin II Antagonist Losartan. Am. CardioL 83(4), 477–481 (1999).
  • ••First large randomized trial of ARBcompared with ACE inhibitors in post-MI patients.
  • Dickstein K, Kjekshus J, and the OPTIMAAL steering committee of the OPTIMAAL study group. Effects of Losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 360,752–760 (2002).
  • Cohn JN, Tognoni G et al. A randomized trial of the angiotensin receptor blacker valsartan in chronic heart failure. N Engl. Med. 345,1667–1675 (2001).
  • Cohn JN. Lessons learned from the valsartan — heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure. Am.j CardioL 90(9), 992–993 (2002).
  • Carson P, Tognoni G, Cohn JN. Effect of valsartan on hospitalization: results from Val-HeFT. J. Card. Fail. (3), 164–171 (2003).
  • Swedberg K, Pfeffer M, Granger C et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Program Investigators. I Card. Fail. (3), 276–282 (1999).
  • Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality an morbidity in patients with chronic heart failure: the CHARM-overall program. Lancet362, 759–766 (2003).
  • ••Major trial for additional benefit ofcombination therapy of ACE inhibitor and ARB in patients with congestive heart failure.
  • McMurray JJV, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 362, 767–771 (2003).
  • Granger BG, McMurray JJV, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 362, 772–776 (2003).
  • Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362,777–781 (2003).
  • Pfeffer MA, McMurray J, Leizorovicz A et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am. Heart J. 140(5), 727–750 (2000).
  • •• Major trial indicating equivalency of ARBs with ACE inhibitors in post-MI patients.
  • Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl. J. Med. 349, 1893–1906 (2003).
  • Mazzolai L, Maillard M, Rossat J et al. Angiotensin II receptor blockade in normotensive subjects. A direct comparison of three AT1 receptor antagonists. Hypertension 33,850–855 (1999).
  • Maillard MR Wurzner G, Nussberger J et al. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin. Pharmacol Ther. 71,68–76 (2002).
  • Mann DL, Deswal A. angiotensin receptor blockade in acute myocardial infarction: a matter of dose. N Engl. J. Med. 349,1963–1965 (2003).
  • Rouleau JL, de Champlain J, Klein M et al. Activation of neurohormonal systems in postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol 22(2), 390–398 (1993).
  • Sigurdsson A, Swedberg K. Neurohormonal activation and congestive heart failure: todays experience with ACE inhibitors and rationale for their use. Eur Heart 16(Suppl. N), 65–72 (1995).
  • Vaughan DE, Lamas GA, Pfeffer MA. Role of left ventricular dysfunction in selective neurohormonal activation in the recovery phase of anterior wall acute myocardial infarction. Am. J Cardiol 66(5), 529–532 (1990).
  • Unger T The ongoing telmisartan alone and in combination with ramipril global end point trial program. Am. J Cardiol 91(10A), G28—G34 (2003).
  • Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blacker, in patients with left ventricular dysfunction after myocardial infarction. N Engl. J Med. 348, 1309–1321 (2003).
  • Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 19,355 (9204), 637–645 (2000).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.